Roche Diagnostics Operations, Inc.

University of Toronto

Roche Diagnostics Gmbh

F. Hoffmann-la Roche Ag

Sara Arab

Georg Hess

Ursula-Henrike Wienhues-Thelen

Dirk Block

Peter Liu

Andrew Emili

Hendrik Huedig

Anthony Gramolini

David MacLennan

Hendrik Heudig

The disclosure relates to assessing heart failure in vitro by measuring the concentration of the marker mimecan in a sample, and optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration of mimecan and the one or more other marker(s) to reference concentrations of this (or these) marker(s) as established in a reference population. The one or more markers may be selected from the group comprising a natriuretic peptide marker, a cardiac troponin marker, and a marker of inflammation. Also disclosed are the use of mimecan as a marker protein in the assessment of heart failure, a marker combination comprising mimecan, and a kit for measuring mimecan.

Use of mimecan in the assessment of heart failure

Disclosed is a method for assessing heart failure in vitro including the steps of measuring in a sample the concentration of the marker SFRP-3, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for SFRP-3 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of SFRP-3 as a marker protein in the assessment of heart failure, a marker combination comprising SFRP-3 and a kit for measuring SFRP-3.

Use of SFRP-3 in the assessment of heart failure

Growing community of inventors

Toronto, Canada

Sara Arab